Batavia Biosciences, a CDMO specializing in development and manufacturing of vaccines and viral vectors, has partnered with Vaccine Biotechnology City (VBC) and MEVAC—two pioneering organizations in Egypt—to enhance local vaccine manufacturing capabilities, focusing initially on Measles, Rubella, and Rotavirus vaccines.

This collaboration underscores Batavia Bioscience’s commitment to addressing global health inequities by transferring advanced technologies, and know-how to support sustainable vaccine production in underserved regions. Through this partnership, Batavia will license proprietary processes, analytical methods, and production systems to VBC and MEVAC, empowering them to produce high-quality vaccines locally and meet international standards.

The collaboration builds on a previously signed license agreement for Measles and Rubella vaccines, with negotiations for Rotavirus vaccines currently underway. This partnership positions Egypt as a vital player in vaccine manufacturing, contributing to greater vaccine self-reliance for the Middle East and Africa. By supporting local production, this initiative aims to ensure wider access to affordable vaccines, particularly in regions most impacted by vaccine-preventable diseases.

Ahd Hamidi, Strategic Partnership Director at Batavia Biosciences, stated: “This collaboration reflects our mission to deliver affordable and accessible vaccine solutions to regions where they are most needed. By enabling local vaccine production, we aim to empower Egypt as a critical player in the fight against preventable diseases in Africa and beyond.”

As the collaboration progresses, Batavia, VBC, and MEVAC will continue to work closely to achieve sustainable vaccine production in Egypt. With discussions for Rotavirus vaccines advancing, the partnership is set to make a lasting impact on public health outcomes across Africa and the Middle East.